Cue Health, a healthcare technology company, announces an industry breakthrough as the first company to receive De Novo authorization from the U.S. Food and Drug Administration (FDA) for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that it has entered a strategic collaboration with Merck KGaA, Darmstadt, Germany to develop FoundationOne®Liquid CDx and FoundationOne®CDx as companion diagnostics in the U.S. market for selected marketed and pipeline treatments.

Boulder, Colorado-based Transformative Biotech announced on Thursday that it has acquired extraction-free, direct-to-PCR technologies from Summit Biolabs for undisclosed terms.

A French team led by investigators at Institut Cochin in Paris has received €1.5 million ($1.7 million) in EU funding to develop biomarkers for endometriosis, a condition where tissue similar to the lining of a woman's uterus grows outside of it.

Quest Diagnostics and Haystack Oncology said Thursday that they have reached a definitive agreement for Quest to acquire Haystack for up to $450 million in cash.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

OpGen announced on Tuesday that it has entered into a distribution partnership for its Unyvero A50 system and in vitro diagnostic tests with Fisher Healthcare, a division of Thermo Fisher Scientific.

Molecular pathology firm Xyall and digital pathology firm Indica Labs said Monday that they have inked a global partnership to combine their technologies to deliver a fully digital and automated workflow for tissue macro dissection for molecular diagnostic testing.

The UK National Health Service said last week that it would offer genetic testing for Lynch syndrome to all patients diagnosed with bowel and endometrial cancer.

On April 7, 2023, the "Molecular Diagnostics Joint Laboratory" jointly built by the Key Laboratory of Medical Molecular Virology of Fudan University, Ministry of Education/Health and Health Commission/ Academy of Medical Sciences and Liferiver Bio-Tech.